Citigroup
OCUL icon

Citigroup’s Ocular Therapeutix OCUL Stock Holding History

Citigroup’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-17,400
Closed -$77K – 7775
2019
Q2 		$77K Buy
17,400
+2,200
+14% +$8.14K ﹤0.01% 6104
2019
Q1 		$60K Buy
15,200
+4,600
+43% +$18.5K ﹤0.01% 6188
2018
Q4 		$42K Sell
10,600
-11,300
-52% -$62.3K ﹤0.01% 6378
2018
Q3 		$151K Buy
21,900
+19,200
+711% +$120K ﹤0.01% 5516
2018
Q2 		$18K Sell
2,700
-1,700
-39% -$11.7K ﹤0.01% 6974
2018
Q1 		$29K Buy
4,400
+3,100
+238% +$17.4K ﹤0.01% 6529
2017
Q4 		$6K Sell
1,300
-2,900
-69% -$14.8K ﹤0.01% 7189
2017
Q3 		$26K Sell
4,200
-12,400
-75% -$79.8K ﹤0.01% 6341
2017
Q2 		$154K Buy
16,600
+1,800
+12% +$17.4K ﹤0.01% 5007
2017
Q1 		$137K Buy
+14,800
New +$123K ﹤0.01% 4965

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citigroup's OCUL Position: Q2 2026 in Review

Citigroup increased its Ocular Therapeutix (OCUL) stake by 152% in Q2 2026, buying an estimated $770K and bringing the position to 140,718 shares worth $1.38M. The position accounts for ﹤0.01% of the portfolio, ranked #3215.

Citigroup first reported a position in OCUL in Q3 2014 and has held it in 46 quarters since. The position peaked at $7.87M in Q3 2025. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Citigroup held 140,718 shares of Ocular Therapeutix worth $1.38M as of Q2 2026.
  • Citigroup bought 84,941 Ocular Therapeutix shares in Q2 2026, an estimated $770K.
  • Ocular Therapeutix made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #3215 holding.
  • Citigroup first reported a position in Ocular Therapeutix in Q3 2014 and has held it in 46 quarters since.
  • Citigroup's Ocular Therapeutix position peaked at $7.87M in Q3 2025.
  • 262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.